Stimuvax Will Become Decision Resources’ Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer
March 13, 2010 – 5:21 pmDecision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that Merck KGaA/Oncothyreon’s Stimuvax vaccine earns Decision Resources’ proprietary clinical gold standard status in 2013 and 2018 for the treatment of locally advanced non-small-cell lung cancer. Available data from Phase II clinical trials of Stimuvax have shown promising median overall survival and tumor response rates in patients when the drug is used as a maintenance therapy following chemoradiotherapy…
Related Info :
Tags: Advanced, Advisory Firms, Become, cancer, Cancer Decision, Cell Lung Cancer, Clinical, Clinical Trials, Decision, Decision Resources, Gold, Gold Standard, Healthcare Issues, Leading Research, Locally, Lung, Lung Cancer, Maintenance Therapy, Merck, Merck Kgaa, Non Small Cell Lung Cancer, NonSmallCell, Pharmaceutical, Phase Ii, Proprietary, Resources, Response Rates, Small Cell Lung Cancer, Standard, Stimuvax, survival, Treatment, Tumor Response
4 Responses to “Stimuvax Will Become Decision Resources’ Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer”
lung cancer could kill you in just a day so stop smoking as early as possible*.~
By Body Pillow on Oct 12, 2010
lung cancer can be prevented by avoiding cigarette smoking and polluted air**”
By Dry Scalp Treatment : on Oct 24, 2010
when you smoke too much, then you are at risk from lung cancer so stay away from developing a bad habit of cigarette smoking *~’
By Fire Grate on Dec 14, 2010
Thanks for the revealing really usefull. I would choose to bookmark this site.
By Long Beach Water Damage on Jan 7, 2011